Global Human Vaccines Administered Orally Market Growth 2024-2031

Report ID: 1344786 | Published Date: Jan 2025 | No. of Page: 116 | Base Year: 2024 | Rating: 4 | Webstory: Check our Web story
Request Sample Report
Pre-Order Enquiry
Request Discount(%) 
1 Scope of the Report
    1.1 Market Introduction
    1.2 Years Considered
    1.3 Research Objectives
    1.4 Market Research Methodology
    1.5 Research Process and Data Source
    1.6 Economic Indicators
    1.7 Currency Considered
2 Executive Summary
    2.1 World Market Overview
        2.1.1 Global Human Vaccines Administered Orally Annual Sales 2017-2028
        2.1.2 World Current & Future Analysis for Human Vaccines Administered Orally by Geographic Region, 2017, 2022 & 2028
        2.1.3 World Current & Future Analysis for Human Vaccines Administered Orally by Country/Region, 2017, 2022 & 2028
    2.2 Human Vaccines Administered Orally Segment by Type
        2.2.1 Rotavirus Vaccine
        2.2.2 Cholera Vaccine
        2.2.3 Oral Polio Vaccine
    2.3 Human Vaccines Administered Orally Sales by Type
        2.3.1 Global Human Vaccines Administered Orally Sales Market Share by Type (2017-2022)
        2.3.2 Global Human Vaccines Administered Orally Revenue and Market Share by Type (2017-2022)
        2.3.3 Global Human Vaccines Administered Orally Sale Price by Type (2017-2022)
    2.4 Human Vaccines Administered Orally Segment by Application
        2.4.1 Public
        2.4.2 Private
    2.5 Human Vaccines Administered Orally Sales by Application
        2.5.1 Global Human Vaccines Administered Orally Sale Market Share by Application (2017-2022)
        2.5.2 Global Human Vaccines Administered Orally Revenue and Market Share by Application (2017-2022)
        2.5.3 Global Human Vaccines Administered Orally Sale Price by Application (2017-2022)
3 Global Human Vaccines Administered Orally by Company
    3.1 Global Human Vaccines Administered Orally Breakdown Data by Company
        3.1.1 Global Human Vaccines Administered Orally Annual Sales by Company (2020-2022)
        3.1.2 Global Human Vaccines Administered Orally Sales Market Share by Company (2020-2022)
    3.2 Global Human Vaccines Administered Orally Annual Revenue by Company (2020-2022)
        3.2.1 Global Human Vaccines Administered Orally Revenue by Company (2020-2022)
        3.2.2 Global Human Vaccines Administered Orally Revenue Market Share by Company (2020-2022)
    3.3 Global Human Vaccines Administered Orally Sale Price by Company
    3.4 Key Manufacturers Human Vaccines Administered Orally Producing Area Distribution, Sales Area, Product Type
        3.4.1 Key Manufacturers Human Vaccines Administered Orally Product Location Distribution
        3.4.2 Players Human Vaccines Administered Orally Products Offered
    3.5 Market Concentration Rate Analysis
        3.5.1 Competition Landscape Analysis
        3.5.2 Concentration Ratio (CR3, CR5 and CR10) & (2020-2022)
    3.6 New Products and Potential Entrants
    3.7 Mergers & Acquisitions, Expansion
4 World Historic Review for Human Vaccines Administered Orally by Geographic Region
    4.1 World Historic Human Vaccines Administered Orally Market Size by Geographic Region (2017-2022)
        4.1.1 Global Human Vaccines Administered Orally Annual Sales by Geographic Region (2017-2022)
        4.1.2 Global Human Vaccines Administered Orally Annual Revenue by Geographic Region
    4.2 World Historic Human Vaccines Administered Orally Market Size by Country/Region (2017-2022)
        4.2.1 Global Human Vaccines Administered Orally Annual Sales by Country/Region (2017-2022)
        4.2.2 Global Human Vaccines Administered Orally Annual Revenue by Country/Region
    4.3 Americas Human Vaccines Administered Orally Sales Growth
    4.4 APAC Human Vaccines Administered Orally Sales Growth
    4.5 Europe Human Vaccines Administered Orally Sales Growth
    4.6 Middle East & Africa Human Vaccines Administered Orally Sales Growth
5 Americas
    5.1 Americas Human Vaccines Administered Orally Sales by Country
        5.1.1 Americas Human Vaccines Administered Orally Sales by Country (2017-2022)
        5.1.2 Americas Human Vaccines Administered Orally Revenue by Country (2017-2022)
    5.2 Americas Human Vaccines Administered Orally Sales by Type
    5.3 Americas Human Vaccines Administered Orally Sales by Application
    5.4 United States
    5.5 Canada
    5.6 Mexico
    5.7 Brazil
6 APAC
    6.1 APAC Human Vaccines Administered Orally Sales by Region
        6.1.1 APAC Human Vaccines Administered Orally Sales by Region (2017-2022)
        6.1.2 APAC Human Vaccines Administered Orally Revenue by Region (2017-2022)
    6.2 APAC Human Vaccines Administered Orally Sales by Type
    6.3 APAC Human Vaccines Administered Orally Sales by Application
    6.4 China
    6.5 Japan
    6.6 South Korea
    6.7 Southeast Asia
    6.8 India
    6.9 Australia
    6.10 China Taiwan
7 Europe
    7.1 Europe Human Vaccines Administered Orally by Country
        7.1.1 Europe Human Vaccines Administered Orally Sales by Country (2017-2022)
        7.1.2 Europe Human Vaccines Administered Orally Revenue by Country (2017-2022)
    7.2 Europe Human Vaccines Administered Orally Sales by Type
    7.3 Europe Human Vaccines Administered Orally Sales by Application
    7.4 Germany
    7.5 France
    7.6 UK
    7.7 Italy
    7.8 Russia
8 Middle East & Africa
    8.1 Middle East & Africa Human Vaccines Administered Orally by Country
        8.1.1 Middle East & Africa Human Vaccines Administered Orally Sales by Country (2017-2022)
        8.1.2 Middle East & Africa Human Vaccines Administered Orally Revenue by Country (2017-2022)
    8.2 Middle East & Africa Human Vaccines Administered Orally Sales by Type
    8.3 Middle East & Africa Human Vaccines Administered Orally Sales by Application
    8.4 Egypt
    8.5 South Africa
    8.6 Israel
    8.7 Turkey
    8.8 GCC Countries
9 Market Drivers, Challenges and Trends
    9.1 Market Drivers & Growth Opportunities
    9.2 Market Challenges & Risks
    9.3 Industry Trends
10 Manufacturing Cost Structure Analysis
    10.1 Raw Material and Suppliers
    10.2 Manufacturing Cost Structure Analysis of Human Vaccines Administered Orally
    10.3 Manufacturing Process Analysis of Human Vaccines Administered Orally
    10.4 Industry Chain Structure of Human Vaccines Administered Orally
11 Marketing, Distributors and Customer
    11.1 Sales Channel
        11.1.1 Direct Channels
        11.1.2 Indirect Channels
    11.2 Human Vaccines Administered Orally Distributors
    11.3 Human Vaccines Administered Orally Customer
12 World Forecast Review for Human Vaccines Administered Orally by Geographic Region
    12.1 Global Human Vaccines Administered Orally Market Size Forecast by Region
        12.1.1 Global Human Vaccines Administered Orally Forecast by Region (2023-2028)
        12.1.2 Global Human Vaccines Administered Orally Annual Revenue Forecast by Region (2023-2028)
    12.2 Americas Forecast by Country
    12.3 APAC Forecast by Region
    12.4 Europe Forecast by Country
    12.5 Middle East & Africa Forecast by Country
    12.6 Global Human Vaccines Administered Orally Forecast by Type
    12.7 Global Human Vaccines Administered Orally Forecast by Application
13 Key Players Analysis
    13.1 Merck
        13.1.1 Merck Company Information
        13.1.2 Merck Human Vaccines Administered Orally Product Offered
        13.1.3 Merck Human Vaccines Administered Orally Sales, Revenue, Price and Gross Margin (2020-2022)
        13.1.4 Merck Main Business Overview
        13.1.5 Merck Latest Developments
    13.2 GSK
        13.2.1 GSK Company Information
        13.2.2 GSK Human Vaccines Administered Orally Product Offered
        13.2.3 GSK Human Vaccines Administered Orally Sales, Revenue, Price and Gross Margin (2020-2022)
        13.2.4 GSK Main Business Overview
        13.2.5 GSK Latest Developments
    13.3 Sanofi
        13.3.1 Sanofi Company Information
        13.3.2 Sanofi Human Vaccines Administered Orally Product Offered
        13.3.3 Sanofi Human Vaccines Administered Orally Sales, Revenue, Price and Gross Margin (2020-2022)
        13.3.4 Sanofi Main Business Overview
        13.3.5 Sanofi Latest Developments
    13.4 Lanzhou Institute
        13.4.1 Lanzhou Institute Company Information
        13.4.2 Lanzhou Institute Human Vaccines Administered Orally Product Offered
        13.4.3 Lanzhou Institute Human Vaccines Administered Orally Sales, Revenue, Price and Gross Margin (2020-2022)
        13.4.4 Lanzhou Institute Main Business Overview
        13.4.5 Lanzhou Institute Latest Developments
    13.5 Serum Institute
        13.5.1 Serum Institute Company Information
        13.5.2 Serum Institute Human Vaccines Administered Orally Product Offered
        13.5.3 Serum Institute Human Vaccines Administered Orally Sales, Revenue, Price and Gross Margin (2020-2022)
        13.5.4 Serum Institute Main Business Overview
        13.5.5 Serum Institute Latest Developments
    13.6 Valneva
        13.6.1 Valneva Company Information
        13.6.2 Valneva Human Vaccines Administered Orally Product Offered
        13.6.3 Valneva Human Vaccines Administered Orally Sales, Revenue, Price and Gross Margin (2020-2022)
        13.6.4 Valneva Main Business Overview
        13.6.5 Valneva Latest Developments
    13.7 Shanghai United Cell
        13.7.1 Shanghai United Cell Company Information
        13.7.2 Shanghai United Cell Human Vaccines Administered Orally Product Offered
        13.7.3 Shanghai United Cell Human Vaccines Administered Orally Sales, Revenue, Price and Gross Margin (2020-2022)
        13.7.4 Shanghai United Cell Main Business Overview
        13.7.5 Shanghai United Cell Latest Developments
    13.8 Bibcol
        13.8.1 Bibcol Company Information
        13.8.2 Bibcol Human Vaccines Administered Orally Product Offered
        13.8.3 Bibcol Human Vaccines Administered Orally Sales, Revenue, Price and Gross Margin (2020-2022)
        13.8.4 Bibcol Main Business Overview
        13.8.5 Bibcol Latest Developments
    13.9 PaxVax
        13.9.1 PaxVax Company Information
        13.9.2 PaxVax Human Vaccines Administered Orally Product Offered
        13.9.3 PaxVax Human Vaccines Administered Orally Sales, Revenue, Price and Gross Margin (2020-2022)
        13.9.4 PaxVax Main Business Overview
        13.9.5 PaxVax Latest Developments
    13.10 Vabiotech
        13.10.1 Vabiotech Company Information
        13.10.2 Vabiotech Human Vaccines Administered Orally Product Offered
        13.10.3 Vabiotech Human Vaccines Administered Orally Sales, Revenue, Price and Gross Margin (2020-2022)
        13.10.4 Vabiotech Main Business Overview
        13.10.5 Vabiotech Latest Developments
    13.11 Tiantan Biological
        13.11.1 Tiantan Biological Company Information
        13.11.2 Tiantan Biological Human Vaccines Administered Orally Product Offered
        13.11.3 Tiantan Biological Human Vaccines Administered Orally Sales, Revenue, Price and Gross Margin (2020-2022)
        13.11.4 Tiantan Biological Main Business Overview
        13.11.5 Tiantan Biological Latest Developments
    13.12 EuBiologics
        13.12.1 EuBiologics Company Information
        13.12.2 EuBiologics Human Vaccines Administered Orally Product Offered
        13.12.3 EuBiologics Human Vaccines Administered Orally Sales, Revenue, Price and Gross Margin (2020-2022)
        13.12.4 EuBiologics Main Business Overview
        13.12.5 EuBiologics Latest Developments
    13.13 Panacea Biotec Ltd
        13.13.1 Panacea Biotec Ltd Company Information
        13.13.2 Panacea Biotec Ltd Human Vaccines Administered Orally Product Offered
        13.13.3 Panacea Biotec Ltd Human Vaccines Administered Orally Sales, Revenue, Price and Gross Margin (2020-2022)
        13.13.4 Panacea Biotec Ltd Main Business Overview
        13.13.5 Panacea Biotec Ltd Latest Developments
    13.14 Bio-Med
        13.14.1 Bio-Med Company Information
        13.14.2 Bio-Med Human Vaccines Administered Orally Product Offered
        13.14.3 Bio-Med Human Vaccines Administered Orally Sales, Revenue, Price and Gross Margin (2020-2022)
        13.14.4 Bio-Med Main Business Overview
        13.14.5 Bio-Med Latest Developments
    13.15 Halfkin Bio-Pharmaceuticals
        13.15.1 Halfkin Bio-Pharmaceuticals Company Information
        13.15.2 Halfkin Bio-Pharmaceuticals Human Vaccines Administered Orally Product Offered
        13.15.3 Halfkin Bio-Pharmaceuticals Human Vaccines Administered Orally Sales, Revenue, Price and Gross Margin (2020-2022)
        13.15.4 Halfkin Bio-Pharmaceuticals Main Business Overview
        13.15.5 Halfkin Bio-Pharmaceuticals Latest Developments
14 Research Findings and Conclusion

List of Tables
    Table 1. Human Vaccines Administered Orally Annual Sales CAGR by Geographic Region (2017, 2022 & 2028) & ($ millions)
    Table 2. Human Vaccines Administered Orally Annual Sales CAGR by Country/Region (2017, 2022 & 2028) & ($ millions)
    Table 3. Major Players of Rotavirus Vaccine
    Table 4. Major Players of Cholera Vaccine
    Table 5. Major Players of Oral Polio Vaccine
    Table 6. Global Human Vaccines Administered Orally Sales by Type (2017-2022) & (K Units)
    Table 7. Global Human Vaccines Administered Orally Sales Market Share by Type (2017-2022)
    Table 8. Global Human Vaccines Administered Orally Revenue by Type (2017-2022) & ($ million)
    Table 9. Global Human Vaccines Administered Orally Revenue Market Share by Type (2017-2022)
    Table 10. Global Human Vaccines Administered Orally Sale Price by Type (2017-2022) & (US$/Unit)
    Table 11. Global Human Vaccines Administered Orally Sales by Application (2017-2022) & (K Units)
    Table 12. Global Human Vaccines Administered Orally Sales Market Share by Application (2017-2022)
    Table 13. Global Human Vaccines Administered Orally Revenue by Application (2017-2022)
    Table 14. Global Human Vaccines Administered Orally Revenue Market Share by Application (2017-2022)
    Table 15. Global Human Vaccines Administered Orally Sale Price by Application (2017-2022) & (US$/Unit)
    Table 16. Global Human Vaccines Administered Orally Sales by Company (2020-2022) & (K Units)
    Table 17. Global Human Vaccines Administered Orally Sales Market Share by Company (2020-2022)
    Table 18. Global Human Vaccines Administered Orally Revenue by Company (2020-2022) ($ Millions)
    Table 19. Global Human Vaccines Administered Orally Revenue Market Share by Company (2020-2022)
    Table 20. Global Human Vaccines Administered Orally Sale Price by Company (2020-2022) & (US$/Unit)
    Table 21. Key Manufacturers Human Vaccines Administered Orally Producing Area Distribution and Sales Area
    Table 22. Players Human Vaccines Administered Orally Products Offered
    Table 23. Human Vaccines Administered Orally Concentration Ratio (CR3, CR5 and CR10) & (2020-2022)
    Table 24. New Products and Potential Entrants
    Table 25. Mergers & Acquisitions, Expansion
    Table 26. Global Human Vaccines Administered Orally Sales by Geographic Region (2017-2022) & (K Units)
    Table 27. Global Human Vaccines Administered Orally Sales Market Share Geographic Region (2017-2022)
    Table 28. Global Human Vaccines Administered Orally Revenue by Geographic Region (2017-2022) & ($ millions)
    Table 29. Global Human Vaccines Administered Orally Revenue Market Share by Geographic Region (2017-2022)
    Table 30. Global Human Vaccines Administered Orally Sales by Country/Region (2017-2022) & (K Units)
    Table 31. Global Human Vaccines Administered Orally Sales Market Share by Country/Region (2017-2022)
    Table 32. Global Human Vaccines Administered Orally Revenue by Country/Region (2017-2022) & ($ millions)
    Table 33. Global Human Vaccines Administered Orally Revenue Market Share by Country/Region (2017-2022)
    Table 34. Americas Human Vaccines Administered Orally Sales by Country (2017-2022) & (K Units)
    Table 35. Americas Human Vaccines Administered Orally Sales Market Share by Country (2017-2022)
    Table 36. Americas Human Vaccines Administered Orally Revenue by Country (2017-2022) & ($ Millions)
    Table 37. Americas Human Vaccines Administered Orally Revenue Market Share by Country (2017-2022)
    Table 38. Americas Human Vaccines Administered Orally Sales by Type (2017-2022) & (K Units)
    Table 39. Americas Human Vaccines Administered Orally Sales Market Share by Type (2017-2022)
    Table 40. Americas Human Vaccines Administered Orally Sales by Application (2017-2022) & (K Units)
    Table 41. Americas Human Vaccines Administered Orally Sales Market Share by Application (2017-2022)
    Table 42. APAC Human Vaccines Administered Orally Sales by Region (2017-2022) & (K Units)
    Table 43. APAC Human Vaccines Administered Orally Sales Market Share by Region (2017-2022)
    Table 44. APAC Human Vaccines Administered Orally Revenue by Region (2017-2022) & ($ Millions)
    Table 45. APAC Human Vaccines Administered Orally Revenue Market Share by Region (2017-2022)
    Table 46. APAC Human Vaccines Administered Orally Sales by Type (2017-2022) & (K Units)
    Table 47. APAC Human Vaccines Administered Orally Sales Market Share by Type (2017-2022)
    Table 48. APAC Human Vaccines Administered Orally Sales by Application (2017-2022) & (K Units)
    Table 49. APAC Human Vaccines Administered Orally Sales Market Share by Application (2017-2022)
    Table 50. Europe Human Vaccines Administered Orally Sales by Country (2017-2022) & (K Units)
    Table 51. Europe Human Vaccines Administered Orally Sales Market Share by Country (2017-2022)
    Table 52. Europe Human Vaccines Administered Orally Revenue by Country (2017-2022) & ($ Millions)
    Table 53. Europe Human Vaccines Administered Orally Revenue Market Share by Country (2017-2022)
    Table 54. Europe Human Vaccines Administered Orally Sales by Type (2017-2022) & (K Units)
    Table 55. Europe Human Vaccines Administered Orally Sales Market Share by Type (2017-2022)
    Table 56. Europe Human Vaccines Administered Orally Sales by Application (2017-2022) & (K Units)
    Table 57. Europe Human Vaccines Administered Orally Sales Market Share by Application (2017-2022)
    Table 58. Middle East & Africa Human Vaccines Administered Orally Sales by Country (2017-2022) & (K Units)
    Table 59. Middle East & Africa Human Vaccines Administered Orally Sales Market Share by Country (2017-2022)
    Table 60. Middle East & Africa Human Vaccines Administered Orally Revenue by Country (2017-2022) & ($ Millions)
    Table 61. Middle East & Africa Human Vaccines Administered Orally Revenue Market Share by Country (2017-2022)
    Table 62. Middle East & Africa Human Vaccines Administered Orally Sales by Type (2017-2022) & (K Units)
    Table 63. Middle East & Africa Human Vaccines Administered Orally Sales Market Share by Type (2017-2022)
    Table 64. Middle East & Africa Human Vaccines Administered Orally Sales by Application (2017-2022) & (K Units)
    Table 65. Middle East & Africa Human Vaccines Administered Orally Sales Market Share by Application (2017-2022)
    Table 66. Key Market Drivers & Growth Opportunities of Human Vaccines Administered Orally
    Table 67. Key Market Challenges & Risks of Human Vaccines Administered Orally
    Table 68. Key Industry Trends of Human Vaccines Administered Orally
    Table 69. Human Vaccines Administered Orally Raw Material
    Table 70. Key Suppliers of Raw Materials
    Table 71. Human Vaccines Administered Orally Distributors List
    Table 72. Human Vaccines Administered Orally Customer List
    Table 73. Global Human Vaccines Administered Orally Sales Forecast by Region (2023-2028) & (K Units)
    Table 74. Global Human Vaccines Administered Orally Sales Market Forecast by Region
    Table 75. Global Human Vaccines Administered Orally Revenue Forecast by Region (2023-2028) & ($ millions)
    Table 76. Global Human Vaccines Administered Orally Revenue Market Share Forecast by Region (2023-2028)
    Table 77. Americas Human Vaccines Administered Orally Sales Forecast by Country (2023-2028) & (K Units)
    Table 78. Americas Human Vaccines Administered Orally Revenue Forecast by Country (2023-2028) & ($ millions)
    Table 79. APAC Human Vaccines Administered Orally Sales Forecast by Region (2023-2028) & (K Units)
    Table 80. APAC Human Vaccines Administered Orally Revenue Forecast by Region (2023-2028) & ($ millions)
    Table 81. Europe Human Vaccines Administered Orally Sales Forecast by Country (2023-2028) & (K Units)
    Table 82. Europe Human Vaccines Administered Orally Revenue Forecast by Country (2023-2028) & ($ millions)
    Table 83. Middle East & Africa Human Vaccines Administered Orally Sales Forecast by Country (2023-2028) & (K Units)
    Table 84. Middle East & Africa Human Vaccines Administered Orally Revenue Forecast by Country (2023-2028) & ($ millions)
    Table 85. Global Human Vaccines Administered Orally Sales Forecast by Type (2023-2028) & (K Units)
    Table 86. Global Human Vaccines Administered Orally Sales Market Share Forecast by Type (2023-2028)
    Table 87. Global Human Vaccines Administered Orally Revenue Forecast by Type (2023-2028) & ($ Millions)
    Table 88. Global Human Vaccines Administered Orally Revenue Market Share Forecast by Type (2023-2028)
    Table 89. Global Human Vaccines Administered Orally Sales Forecast by Application (2023-2028) & (K Units)
    Table 90. Global Human Vaccines Administered Orally Sales Market Share Forecast by Application (2023-2028)
    Table 91. Global Human Vaccines Administered Orally Revenue Forecast by Application (2023-2028) & ($ Millions)
    Table 92. Global Human Vaccines Administered Orally Revenue Market Share Forecast by Application (2023-2028)
    Table 93. Merck Basic Information, Human Vaccines Administered Orally Manufacturing Base, Sales Area and Its Competitors
    Table 94. Merck Human Vaccines Administered Orally Product Offered
    Table 95. Merck Human Vaccines Administered Orally Sales (K Units), Revenue ($ Million), Price (US$/Unit) and Gross Margin (2020-2022)
    Table 96. Merck Main Business
    Table 97. Merck Latest Developments
    Table 98. GSK Basic Information, Human Vaccines Administered Orally Manufacturing Base, Sales Area and Its Competitors
    Table 99. GSK Human Vaccines Administered Orally Product Offered
    Table 100. GSK Human Vaccines Administered Orally Sales (K Units), Revenue ($ Million), Price (US$/Unit) and Gross Margin (2020-2022)
    Table 101. GSK Main Business
    Table 102. GSK Latest Developments
    Table 103. Sanofi Basic Information, Human Vaccines Administered Orally Manufacturing Base, Sales Area and Its Competitors
    Table 104. Sanofi Human Vaccines Administered Orally Product Offered
    Table 105. Sanofi Human Vaccines Administered Orally Sales (K Units), Revenue ($ Million), Price (US$/Unit) and Gross Margin (2020-2022)
    Table 106. Sanofi Main Business
    Table 107. Sanofi Latest Developments
    Table 108. Lanzhou Institute Basic Information, Human Vaccines Administered Orally Manufacturing Base, Sales Area and Its Competitors
    Table 109. Lanzhou Institute Human Vaccines Administered Orally Product Offered
    Table 110. Lanzhou Institute Human Vaccines Administered Orally Sales (K Units), Revenue ($ Million), Price (US$/Unit) and Gross Margin (2020-2022)
    Table 111. Lanzhou Institute Main Business
    Table 112. Lanzhou Institute Latest Developments
    Table 113. Serum Institute Basic Information, Human Vaccines Administered Orally Manufacturing Base, Sales Area and Its Competitors
    Table 114. Serum Institute Human Vaccines Administered Orally Product Offered
    Table 115. Serum Institute Human Vaccines Administered Orally Sales (K Units), Revenue ($ Million), Price (US$/Unit) and Gross Margin (2020-2022)
    Table 116. Serum Institute Main Business
    Table 117. Serum Institute Latest Developments
    Table 118. Valneva Basic Information, Human Vaccines Administered Orally Manufacturing Base, Sales Area and Its Competitors
    Table 119. Valneva Human Vaccines Administered Orally Product Offered
    Table 120. Valneva Human Vaccines Administered Orally Sales (K Units), Revenue ($ Million), Price (US$/Unit) and Gross Margin (2020-2022)
    Table 121. Valneva Main Business
    Table 122. Valneva Latest Developments
    Table 123. Shanghai United Cell Basic Information, Human Vaccines Administered Orally Manufacturing Base, Sales Area and Its Competitors
    Table 124. Shanghai United Cell Human Vaccines Administered Orally Product Offered
    Table 125. Shanghai United Cell Human Vaccines Administered Orally Sales (K Units), Revenue ($ Million), Price (US$/Unit) and Gross Margin (2020-2022)
    Table 126. Shanghai United Cell Main Business
    Table 127. Shanghai United Cell Latest Developments
    Table 128. Bibcol Basic Information, Human Vaccines Administered Orally Manufacturing Base, Sales Area and Its Competitors
    Table 129. Bibcol Human Vaccines Administered Orally Product Offered
    Table 130. Bibcol Human Vaccines Administered Orally Sales (K Units), Revenue ($ Million), Price (US$/Unit) and Gross Margin (2020-2022)
    Table 131. Bibcol Main Business
    Table 132. Bibcol Latest Developments
    Table 133. PaxVax Basic Information, Human Vaccines Administered Orally Manufacturing Base, Sales Area and Its Competitors
    Table 134. PaxVax Human Vaccines Administered Orally Product Offered
    Table 135. PaxVax Human Vaccines Administered Orally Sales (K Units), Revenue ($ Million), Price (US$/Unit) and Gross Margin (2020-2022)
    Table 136. PaxVax Main Business
    Table 137. PaxVax Latest Developments
    Table 138. Vabiotech Basic Information, Human Vaccines Administered Orally Manufacturing Base, Sales Area and Its Competitors
    Table 139. Vabiotech Human Vaccines Administered Orally Product Offered
    Table 140. Vabiotech Human Vaccines Administered Orally Sales (K Units), Revenue ($ Million), Price (US$/Unit) and Gross Margin (2020-2022)
    Table 141. Vabiotech Main Business
    Table 142. Vabiotech Latest Developments
    Table 143. Tiantan Biological Basic Information, Human Vaccines Administered Orally Manufacturing Base, Sales Area and Its Competitors
    Table 144. Tiantan Biological Human Vaccines Administered Orally Product Offered
    Table 145. Tiantan Biological Human Vaccines Administered Orally Sales (K Units), Revenue ($ Million), Price (US$/Unit) and Gross Margin (2020-2022)
    Table 146. Tiantan Biological Main Business
    Table 147. Tiantan Biological Latest Developments
    Table 148. EuBiologics Basic Information, Human Vaccines Administered Orally Manufacturing Base, Sales Area and Its Competitors
    Table 149. EuBiologics Human Vaccines Administered Orally Product Offered
    Table 150. EuBiologics Human Vaccines Administered Orally Sales (K Units), Revenue ($ Million), Price (US$/Unit) and Gross Margin (2020-2022)
    Table 151. EuBiologics Main Business
    Table 152. EuBiologics Latest Developments
    Table 153. Panacea Biotec Ltd Basic Information, Human Vaccines Administered Orally Manufacturing Base, Sales Area and Its Competitors
    Table 154. Panacea Biotec Ltd Human Vaccines Administered Orally Product Offered
    Table 155. Panacea Biotec Ltd Human Vaccines Administered Orally Sales (K Units), Revenue ($ Million), Price (US$/Unit) and Gross Margin (2020-2022)
    Table 156. Panacea Biotec Ltd Main Business
    Table 157. Panacea Biotec Ltd Latest Developments
    Table 158. Bio-Med Basic Information, Human Vaccines Administered Orally Manufacturing Base, Sales Area and Its Competitors
    Table 159. Bio-Med Human Vaccines Administered Orally Product Offered
    Table 160. Bio-Med Human Vaccines Administered Orally Sales (K Units), Revenue ($ Million), Price (US$/Unit) and Gross Margin (2020-2022)
    Table 161. Bio-Med Main Business
    Table 162. Bio-Med Latest Developments
    Table 163. Halfkin Bio-Pharmaceuticals Basic Information, Human Vaccines Administered Orally Manufacturing Base, Sales Area and Its Competitors
    Table 164. Halfkin Bio-Pharmaceuticals Human Vaccines Administered Orally Product Offered
    Table 165. Halfkin Bio-Pharmaceuticals Human Vaccines Administered Orally Sales (K Units), Revenue ($ Million), Price (US$/Unit) and Gross Margin (2020-2022)
    Table 166. Halfkin Bio-Pharmaceuticals Main Business
    Table 167. Halfkin Bio-Pharmaceuticals Latest Developments
List of Figures
    Figure 1. Picture of Human Vaccines Administered Orally
    Figure 2. Human Vaccines Administered Orally Report Years Considered
    Figure 3. Research Objectives
    Figure 4. Research Methodology
    Figure 5. Research Process and Data Source
    Figure 6. Global Human Vaccines Administered Orally Sales Growth Rate 2017-2028 (K Units)
    Figure 7. Global Human Vaccines Administered Orally Revenue Growth Rate 2017-2028 ($ Millions)
    Figure 8. Human Vaccines Administered Orally Sales by Region (2021 & 2028) & ($ millions)
    Figure 9. Product Picture of Rotavirus Vaccine
    Figure 10. Product Picture of Cholera Vaccine
    Figure 11. Product Picture of Oral Polio Vaccine
    Figure 12. Global Human Vaccines Administered Orally Sales Market Share by Type in 2021
    Figure 13. Global Human Vaccines Administered Orally Revenue Market Share by Type (2017-2022)
    Figure 14. Human Vaccines Administered Orally Consumed in Public
    Figure 15. Global Human Vaccines Administered Orally Market: Public (2017-2022) & (K Units)
    Figure 16. Human Vaccines Administered Orally Consumed in Private
    Figure 17. Global Human Vaccines Administered Orally Market: Private (2017-2022) & (K Units)
    Figure 18. Global Human Vaccines Administered Orally Sales Market Share by Application (2017-2022)
    Figure 19. Global Human Vaccines Administered Orally Revenue Market Share by Application in 2021
    Figure 20. Human Vaccines Administered Orally Revenue Market by Company in 2021 ($ Million)
    Figure 21. Global Human Vaccines Administered Orally Revenue Market Share by Company in 2021
    Figure 22. Global Human Vaccines Administered Orally Sales Market Share by Geographic Region (2017-2022)
    Figure 23. Global Human Vaccines Administered Orally Revenue Market Share by Geographic Region in 2021
    Figure 24. Global Human Vaccines Administered Orally Sales Market Share by Region (2017-2022)
    Figure 25. Global Human Vaccines Administered Orally Revenue Market Share by Country/Region in 2021
    Figure 26. Americas Human Vaccines Administered Orally Sales 2017-2022 (K Units)
    Figure 27. Americas Human Vaccines Administered Orally Revenue 2017-2022 ($ Millions)
    Figure 28. APAC Human Vaccines Administered Orally Sales 2017-2022 (K Units)
    Figure 29. APAC Human Vaccines Administered Orally Revenue 2017-2022 ($ Millions)
    Figure 30. Europe Human Vaccines Administered Orally Sales 2017-2022 (K Units)
    Figure 31. Europe Human Vaccines Administered Orally Revenue 2017-2022 ($ Millions)
    Figure 32. Middle East & Africa Human Vaccines Administered Orally Sales 2017-2022 (K Units)
    Figure 33. Middle East & Africa Human Vaccines Administered Orally Revenue 2017-2022 ($ Millions)
    Figure 34. Americas Human Vaccines Administered Orally Sales Market Share by Country in 2021
    Figure 35. Americas Human Vaccines Administered Orally Revenue Market Share by Country in 2021
    Figure 36. United States Human Vaccines Administered Orally Revenue Growth 2017-2022 ($ Millions)
    Figure 37. Canada Human Vaccines Administered Orally Revenue Growth 2017-2022 ($ Millions)
    Figure 38. Mexico Human Vaccines Administered Orally Revenue Growth 2017-2022 ($ Millions)
    Figure 39. Brazil Human Vaccines Administered Orally Revenue Growth 2017-2022 ($ Millions)
    Figure 40. APAC Human Vaccines Administered Orally Sales Market Share by Region in 2021
    Figure 41. APAC Human Vaccines Administered Orally Revenue Market Share by Regions in 2021
    Figure 42. China Human Vaccines Administered Orally Revenue Growth 2017-2022 ($ Millions)
    Figure 43. Japan Human Vaccines Administered Orally Revenue Growth 2017-2022 ($ Millions)
    Figure 44. South Korea Human Vaccines Administered Orally Revenue Growth 2017-2022 ($ Millions)
    Figure 45. Southeast Asia Human Vaccines Administered Orally Revenue Growth 2017-2022 ($ Millions)
    Figure 46. India Human Vaccines Administered Orally Revenue Growth 2017-2022 ($ Millions)
    Figure 47. Australia Human Vaccines Administered Orally Revenue Growth 2017-2022 ($ Millions)
    Figure 48. Europe Human Vaccines Administered Orally Sales Market Share by Country in 2021
    Figure 49. Europe Human Vaccines Administered Orally Revenue Market Share by Country in 2021
    Figure 50. Germany Human Vaccines Administered Orally Revenue Growth 2017-2022 ($ Millions)
    Figure 51. France Human Vaccines Administered Orally Revenue Growth 2017-2022 ($ Millions)
    Figure 52. UK Human Vaccines Administered Orally Revenue Growth 2017-2022 ($ Millions)
    Figure 53. Italy Human Vaccines Administered Orally Revenue Growth 2017-2022 ($ Millions)
    Figure 54. Russia Human Vaccines Administered Orally Revenue Growth 2017-2022 ($ Millions)
    Figure 55. Middle East & Africa Human Vaccines Administered Orally Sales Market Share by Country in 2021
    Figure 56. Middle East & Africa Human Vaccines Administered Orally Revenue Market Share by Country in 2021
    Figure 57. Egypt Human Vaccines Administered Orally Revenue Growth 2017-2022 ($ Millions)
    Figure 58. South Africa Human Vaccines Administered Orally Revenue Growth 2017-2022 ($ Millions)
    Figure 59. Israel Human Vaccines Administered Orally Revenue Growth 2017-2022 ($ Millions)
    Figure 60. Turkey Human Vaccines Administered Orally Revenue Growth 2017-2022 ($ Millions)
    Figure 61. GCC Country Human Vaccines Administered Orally Revenue Growth 2017-2022 ($ Millions)
    Figure 62. Manufacturing Cost Structure Analysis of Human Vaccines Administered Orally in 2021
    Figure 63. Manufacturing Process Analysis of Human Vaccines Administered Orally
    Figure 64. Industry Chain Structure of Human Vaccines Administered Orally
    Figure 65. Channels of Distribution
    Figure 66. Distributors Profiles
Please ask for List of Figures. Request Sample Report
Companies Included in Reports:
Please ask for Sample Report to see list of companies covered. Request Sample Report
Frequently Asked Questions
Global Human Vaccines Administered Orally Market report offers great insights of the market and consumer data and their interpretation through various figures and graphs. Report has embedded global market and regional market deep analysis through various research methodologies. The report also offers great competitor analysis of the industries and highlights the key aspect of their business like success stories, market development and growth rate.
Global Human Vaccines Administered Orally Market report is categorised based on following features:
  1. Global Market Players
  2. Geopolitical regions
  3. Consumer Insights
  4. Technological advancement
  5. Historic and Future Analysis of the Market
Global Human Vaccines Administered Orally Market report is designed on the six basic aspects of analysing the market, which covers the SWOT and SWAR analysis like strength, weakness, opportunity, threat, aspirations and results. This methodology helps investors to reach on to the desired and correct decision to put their capital into the market.

Related Reports